The increase was primarily related to non cash incentive stock based compensation, payroll benefits and other employee costs, professional services including fees for tax, audit, legal services, financial advisory services and other general business expenses. General administrative expenses for the year ended 12/31/2024 were 17,700,000 as compared to $7,900,000 for the same period in 2023. The increase was primarily related to non cash incentive stock based compensation, professional services, including fees for tax, audit and legal services, financial advisory services, patent prosecution for the nimasumab IT and other general business expenses. The net loss for the year ended 12/31/2024 totaled $26,600,000 with non cash share based compensation expense of $8,300,000 compared to $37,600,000 for the year ended 2023 with non cash share based compensation expense of $1,000,000 The primary reason for the significant decrease related to the acquisition of the nimatumab in process research and development asset for $21,200,000 during the year ended 12/31/2023, all of which was expensed upon acquisition. In addition, during 2024, we recognized a $4,200,000 gain from the partial derecognition of our contingent legal liability and a $2,000,000 gain from the settlement of insurance litigation with our former D and O carrier, $3,000,000 in interest income and a gain of $1,400,000 from the sale of real estate.